Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Use of NexoBrid for Treatment of Acute Deep Partial and Full Thickness Burn Injuries

Next Previous
Trial Profile

Use of NexoBrid for Treatment of Acute Deep Partial and Full Thickness Burn Injuries

Status: Active, no longer recruiting
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 04 Sep 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bromelains (Primary)
  • Indications Burns
  • Focus Adverse reactions; Expanded access; Therapeutic Use
  • Acronyms NEXT
  • Sponsors MediWound

Most Recent Events

  • 30 May 2024 Status changed to active, no longer recruiting, according to Mediwound media release
  • 29 May 2024 According to Mediwound media release, enrollment and 12-month follow-up for the Expanded Access Treatment Protocol (NEXT) have been concluded, 239 burn patients have been treated across 29 U.S. centers. Data readout is anticipated in the second half of 2024.
  • 09 May 2023 According to Mediwound media release, announced that the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS), has awarded an additional $10 million to MediWound. Out of that $3 million will be utilized for sBLA submission to USFDA and enrollment of additional 50 patients in this study.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top